



FIG. 1





DRUG RELEASED, %




FIG. 3

DRUG RELEASED, %




FIG. 4

DRUG RELEASED, %




FIG. 5

FIG. 6





FIG. 7



6/10

FIG. 8






FIG. 9



MEAN PLASMA CONCENTRATION - TIME PROFILES OF LOVASTATIN AND LOVASTATIN ACID IN PATIENTS (n=12) AFTER MULTIPLE-DOSE ADMINISTRATION OF LOVASTATIN XL OR MEVACOR

- LOVASTATIN AFTER LOVASTATIN XL
- LOVASTATIN AFTER MEVACOR
- △— LOVASTATIN ACID AFTER LOVASTATIN XL
- ▲— LOVASTATIN ACID AFTER MEVACOR

DAY 1



DAY 28




FIG.10



MEAN PLASMA CONCENTRATION-TIME PROFILES OF TOTAL AND ACTIVE INHIBITORS OF HMG-COA REDUCTASE IN PATIENTS (n=12) AFTER MULTIPLE-DOSE ADMINISTRATION OF LOVASTATIN XL OR MEVACOR

- TOTAL HMG-COA REDUCTASE INHIBITORS AFTER LOVASTATIN XL
- TOTAL HMG-COA REDUCTASE INHIBITORS AFTER MEVACOR
- △— ACTIVE HMG-COA REDUCTASE INHIBITORS AFTER LOVASTATIN XL
- ▲— ACTIVE HMG-COA REDUCTASE INHIBITORS AFTER MEVACOR




FIG. 11

10 / 10

